Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7566
- PB 5.0504
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.2431
- MktCap 263459252265.0
- FreeCF/Share 5.2238
- PFCF 20.19
- PE 13.7578
- Debt/Assets 0.372
- DivYield 0.0309
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MRK | Wells Fargo | Equal Weight | Overweight | -- | $125 | Nov. 24, 2025 |
| Initiation | MRK | Scotiabank | -- | Sector Outperform | -- | $105 | Nov. 13, 2025 |
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
News
Top 10 High-Yield Dividend Stocks For December 2025
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Positive
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks with attractive valuations, aiming for a 12% long-term CAGR and strong starting yields. Top 10 picks for December include Accenture, EOG Resources, Nike, Paychex, ADP, Penske Automotive, Comcast, Essential Utilities, and Brown Forman.
Read More
Here's Why Merck (MRK) is a Strong Momentum Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Merck: Excellence Across The Board
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance and diversified revenue streams, supports strong profitability and mitigates concentration risk. MRK's proven investment track record and consistent dividend growth further reinforce its appeal as a long-term investment opportunity.
Read More
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
Read More
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
Read More
Pharma Stock Pops on Wells Fargo Upgrade
Published: November 24, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90.
Read More
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Marjorie C. Green - Senior VP & Head of Late-Stage Oncology - Global Clinical Development Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Last day.
Read More
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Read More
Here's Why Merck (MRK) is a Strong Value Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Published: November 19, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve).
Read More
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Read More
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Published: November 18, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).
Read More
Merck Announces First-Quarter 2026 Dividend
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2026 Dividend.
Read More
Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF.
Read More
Merck Has Many Bullish Attributes (Technical Analysis)
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, momentum indicators are bullish, and volume shows institutional accumulation. Since its May low, the company has outperformed the S&P 500, with relative strength now trending higher and above its 30-week EMA.
Read More
Merck & Co., Inc. (MRK) M&A Call Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) M&A Call November 17, 2025 8:00 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Dean Li - Executive VP & President of Merck Research Laboratories Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Caroline Litchfield - Executive VP & CFO Conference Call Participants Carter Gould - Cantor Fitzgerald & Co., Research Division James Shin - Deutsche Bank AG, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Alexandria Hammond …
Read More
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
Read More
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Here's Why Merck (MRK) is a Strong Growth Stock
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Merck to acquire Cidara Therapeutics for $9.2B
Published: November 14, 2025 by: Proactive Investors
Sentiment: Positive
Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it has agreed to acquire Cidara Therapeutics Inc (NASDAQ:CDTX) in a $9.2 billion cash deal, paying $221.50 per share, more than double Cidara's stock price prior to the announcement. Shares of Merck slipped 1.5% to about $92 on the news, while Cidara shares surged 105% to $217.
Read More
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participants Taylor Hanley - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Vamil Divan …
Read More
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Read More
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Merck (MRK) is a Top Value Stock for the Long-Term
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Read More
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & …
Read More
My Top 10 High-Yield Picks For November 2025: One Yields 9%+
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
I present a diversified selection of high-yield dividend stocks with strong income and growth potential, including CVX, VZ, MO, ARCC, and others. Each company was selected for sustainable dividends, attractive yields, reasonable payout ratios, and a proven record or potential for dividend growth. CVX and ARCC receive positive Wall Street ratings, while VZ and MO offer high yields and strong free cash flow, supporting portfolio income stability.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000